Disclosed are compositions comprising a minced chorionic matrix, a homogenized amniotic matrix, and a homogenized umbilical cord (UC) matrix, wherein the minced chorionic matrix comprises viable cells, wherein the composition does not comprise trophoblasts. Disclosed are compositions comprising isolated, viable chorionic cells, a homogenized amniotic matrix, and a homogenized UC matrix, wherein the composition does not comprise trophoblasts. Disclosed are compositions comprising a minced chorionic matrix and a homogenized UC matrix, wherein the minced chorionic matrix comprises viable cells, wherein the composition does not comprise trophoblasts or an amniotic matrix. Disclosed are compositions comprising isolated, viable chorionic cells and a homogenized

UC matrix, wherein the composition does not comprise trophoblasts or an amniotic matrix. Disclosed are methods of treating a tissue injury or chronic pain comprising administering any of the disclosed compositions to an area of a subject comprising a tissue injury.

Disclosed are compositions comprising a minced chorionic matrix, a homogenized amniotic matrix, and a homogenized umbilical cord (UC) matrix, wherein the minced chorionic matrix comprises viable cells, wherein the composition does not comprise trophoblasts. Disclosed are compositions comprising isolated, viable chorionic cells, a homogenized amniotic matrix, and a homogenized UC matrix, wherein the composition does not comprise trophoblasts. Disclosed are compositions comprising a minced chorionic matrix and a homogenized UC matrix, wherein the minced chorionic matrix comprises viable cells, wherein the composition does not comprise trophoblasts or an amniotic matrix. Disclosed are compositions comprising isolated, viable chorionic cells and a homogenized

UC matrix, wherein the composition does not comprise trophoblasts or an amniotic matrix. Disclosed are methods of treating a tissue injury or chronic pain comprising administering any of the disclosed compositions to an area of a subject comprising a tissue injury.

The disclosure is directed to compositions and methods comprising genetically engineered fibroblasts for inhibiting progression of a cancerous tumor.

The disclosure is directed to compositions and methods comprising genetically engineered fibroblasts for inhibiting progression of a cancerous tumor.

Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own skin using current good manufacturing practices (CGMP), and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL, of cells at a concentration of from 1.0-2.0×10.sup.7 cells/mL. When injected into the nasolabial fold wrinkles (creases on the sides of the nose that extend to the corners of the mouth), the autologous fibroblasts are thought to increase the synthesis of extracellular matrix components, including collagen, reducing the severity of these wrinkles. Dosage and timing of administration have been demonstrated to be critical to achieving clinically significant outcomes.

Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own skin using current good manufacturing practices (CGMP), and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL, of cells at a concentration of from 1.0-2.0×10.sup.7 cells/mL. When injected into the nasolabial fold wrinkles (creases on the sides of the nose that extend to the corners of the mouth), the autologous fibroblasts are thought to increase the synthesis of extracellular matrix components, including collagen, reducing the severity of these wrinkles. Dosage and timing of administration have been demonstrated to be critical to achieving clinically significant outcomes.

The present invention provides a method with which it is possible to directly induce nervous system cells efficiently and in a short amount of time. Because the method is easy to scale up and is not affected by the characteristics or background of the somatic cells used as material, the method enables the stable supply of nervous system cells. The nervous system cells obtained by the method are useful in various fields of research and healthcare.

A composition comprising cell-derived particles presenting heterologous CD24, wherein the cell is a non-cancerous cell and wherein the composition is substantially devoid of intact cells is disclosed. Methods of producing the cell-derived particles and methods of using the cell-derived particles in treatment of cytokine storm syndrome, tissue injury associated with the inflammation and Coronavirus infection are also disclosed.

A composition comprising cell-derived particles presenting heterologous CD24, wherein the cell is a non-cancerous cell and wherein the composition is substantially devoid of intact cells is disclosed. Methods of producing the cell-derived particles and methods of using the cell-derived particles in treatment of cytokine storm syndrome, tissue injury associated with the inflammation and Coronavirus infection are also disclosed.

The invention relates to in vitro methods for isolating, or producing selected populations of human epicardial cells derived from human pluripotent stem cells; defined mixtures of said cells, and therapeutic uses thereof. Said population comprises epicardial cells with or without the potential to differentiate into cardiac fibroblasts, or a mixture thereof.